Consistent with our prior study [35], lower-dose TSLPRCART monotherapy completely eradicated detectable human ALL in murine peripheral blood (Fig. 1B, orange) with notable peripheral blood T cell expansion and persistence (Fig. 1C, orange) and peak plasma IFN-γ levels at one week post-treatment (Fig. 1D, orange), as well as long-term animal survival. The gene discussed is IFNG; the disease is acute lymphoblastic leukemia.